Company Profile
InnoCare Pharma Limited, a biopharmaceutical company discovers, develops, and commercializs drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder.
It also developing ICP-B02 to treat CD20+B-cell malignancies. Its portfolio also includes ICP-B05 to treat hemato-oncology, ICP-248 to treat chronic lymphocytic leukemia, ICP-332 to treat atopic dermatitis, ICP-488 to treat psoriasis, ICP-538 to treat autoimmune diseases, zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers, ICP-189 to treat non-small cell lung cancer, and ICP-B05 to treat solid tumor. Incorporated in 2015, InnoCare Pharma is headquartered in Beijing, China.